Trial Details
RecruitingBasic Information
| Clinical ID | c2056 |
|---|---|
| Identifier | CTIS2024-515358-25-00 |
| Trial Title | Investigating the safety, feasibility, and optimal dose of risankizumab-800CW for visualizing drug targeting in Inflammatory Bowel Disease - 20010 |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Inflammatory Bowel Disease (IBD);Therapeutic area: Diseases [C] - Immune System Diseases [C20];Therapeutic area: Diseases [C] - Digestive System Diseases [C06] |
| Interventions | Product Name: Skyrizi 600 mg concentrate for solution for infusion, Product Code:PRD10081867, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: |
Participant Information
| Sponsor | Universitair Medisch Centrum Groningen |
|---|---|
| City | - |
| Country/Region | Netherlands |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | Interventional clinical trial of medicinal product |
|---|---|
| Phase | PHASE1|PHASE2 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |